platinum has been researched along with Central Nervous System Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, Y; Gyotoku, H; Harada, D; Kogure, Y; Murakami, S; Ninomiya, K; Nomura, S; Okamoto, H; Okishio, K; Okuma, Y | 1 |
| Buckner, JC; Erickson, BJ; Gornet, MK; Marks, RS; Scheithauer, BW | 1 |
1 review(s) available for platinum and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study).
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Pemetrexed; Platinum; Protein Kinase Inhibitors | 2023 |
1 other study(ies) available for platinum and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Chemotherapy for advanced CNS ependymoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Disease Progression; Ependymoma; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Middle Aged; Nitrosourea Compounds; Platinum; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 1999 |